RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On April 27, 2017 RenovaCare, Inc. (we,
us or our) issued a press
release announcing that it highlighted an analysis of treatment
results on a variety of wide-area and severe burn injuries
published in Burns, the peer-reviewed Journal of the
International Society for Burn Injuries. The treatment method,
which involved isolating and spraying the patients own skin stem
cells on the burn wounds, is the technology underlying our
patented CellMist and SkinGun.

The results, published in August 2016, report the retrospective
analysis of outcomes in 45 severe second-degree burn patients who
received skin stem cell spray grafting treatment under an
innovative practice approach.

The patients suffered burn wounds such as gas and chemical
explosions, as well as electrical, gasoline, hot water and tar
scalding burns.

A copy of the press release is attached as Exhibit
99.1 hereto.

The information in this Item 7.01 of this Current Report on Form
8-K (this Report) and Exhibit 99.1 attached
hereto shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The
information contained in this Item 7.01 and in the press release
attached as Exhibit 99.1 to this Report shall not be incorporated
by reference into any filing with the SEC made by us, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.

Item 8.01 Other Events.

On April 4, 2017, the U.S. Patent Trademark Office (the
PTO) issued to us U.S. Patent No. 9,610,430
related to our device and method for spraying autologous skin
cells. On or about April 11, 2017, we received from Avita Medical
Limited (Avita) a paper copy of what was labeled
a Petition for Inter Partes Review purporting to
challenge the validity of the claims in U.S. Patent No. 9,610,430
(the Petition) before the Patent Trial and
Appeal Board (PTAB), which is an administrative
proceeding of the PTO (the Proceeding). We do
not agree with the assertions set forth in the Petition and we
intend to defend our intellectual property.

In the event the Proceeding progresses, the PTAB may find (i)
that the Petition is insufficient to establish that any such
claims are unpatentable and accordingly confirm all of the claims
in our U.S. Patent No. 9,610,430 or (ii) one or more claims of
U.S. Patent No. 9,610,430 to be unpatentable and cancel any such
claims and confirm the balance of such claims.

We intend to continue our plan to file additional patent
applications in the United States and elsewhere, as appropriate,
as part of our on-going development of our intellectual property
portfolio.

Except for the historical information presented in this document,
the matters discussed in this Report contain forward-looking
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). These statements are identified
by the use of forward-looking terminology such as believes,
plans, intend, scheduled, potential, continue, estimates, hopes,
goal, objective, expects, may, will, should or anticipates or the
negative thereof or other variations thereon or comparable
terminology, or by discussions of strategy that involve risks and
uncertainties. The safe harbor provisions of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A of
the Securities Act of 1933, as amended, apply to forward-looking
statements made by us. The reader is cautioned that no statements
contained in this Report should be construed as a guarantee or
assurance of future performance or results. These forward-looking
statements involve risks and uncertainties, including those
identified within this Report. The actual results we achieve may
differ materially from any forward-looking statements due to such
risks and uncertainties. These forward-looking statements are
based on current expectations, and we assume no obligation to
update this information. Readers are urged to carefully review
and consider the various disclosures made by us in this Report
and our other reports filed with the Securities and Exchange
Commission that attempt to advise interested parties of the risks
and factors that may affect our business.

Item 9.01 Exhibits.

(d) Exhibits

About RenovaCare, Inc. (OTCMKTS:RCAR)

RenovaCare, Inc., formerly Janus Resources, Inc., is a biotechnology company. The Company is focused on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The Company’s initial products under development target skin. The Company, through RenovaCare Sciences Corp., offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). It is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Its technology, the CellMist System, uses SkinGun to spray a liquid suspension of a patient’s stem cells, the CellMist Solution, onto wounds. The CellMist System harvests a patient’s stem cells from a small area of skin and suspends them in the water-based CellMist Solution.

RenovaCare, Inc. (OTCMKTS:RCAR) Recent Trading Information

RenovaCare, Inc. (OTCMKTS:RCAR) closed its last trading session up +0.15 at 3.55 with 22,100 shares trading hands.